Table 2.
Metabolites associated with ILD in RA.
| ILD(+)RA case 1 + 2 | CLD(–)RA control 1 + 2 | Case 1 + 2 vs. control 1 + 2 | UIP(+)RA case 1 | CLD(–)RA control 1 | Case 1 vs. control 1 | NSIP(+)RA case 2 | CLD(–)RA control 2 | Case 2 vs. control 2 | Meta-analysis of (case 1 vs. control 1) and (case 2 vs. control 2) | Meta-analysis of (case 1 vs. control 1) and (case 2 vs. control 2) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | P | P | P | FDR Q | |||||||
| Decanoic acid | −0.58 (0.62) | 0.59 (0.97) | 3.85 × 10−19 | −0.57 (0.63) | 0.66 (1.06) | 3.92 × 10−9 | −0.58 (0.62) | 0.53 (0.90) | 2.07 × 10−11 | 9.10 × 10−14 | 1.87 × 10−11 |
| Glycerol | 0.44 (0.99) | −0.43 (0.78) | 3.77 × 10−11 | 0.52 (0.89) | −0.60 (0.75) | 2.17 × 10−9 | 0.38 (1.07) | −0.29 (0.79) | 0.0004 | 1.17 × 10−8 | 1.20 × 10−6 |
| Morpholine | −0.43 (0.00) | 0.44 (1.28) | 1.97 × 10−10 | −0.43 (0.00) | 0.33 (1.21) | 7.37 × 10−5 | −0.43 (0.00) | 0.53 (1.34) | 7.44 × 10−7 | 1.04 × 10−7 | 7.09 × 10−6 |
| Dyphylline | 0.37 (0.99) | −0.36 (0.87) | 6.45 × 10−8 | 0.42 (0.93) | −0.60 (0.82) | 1.44 × 10−7 | 0.33 (1.04) | −0.16 (0.87) | 0.0099 | 2.04 × 10−6 | 0.0001 |
| Octanoic acid | −0.32 (0.91) | 0.33 (0.99) | 2.78 × 10−6 | −0.27 (0.94) | 0.55 (1.12) | 0.0003 | −0.37 (0.89) | 0.14 (0.83) | 0.0027 | 0.0002 | 0.0074 |
| Fumaric acid monomethyl ester | −0.30 (0.81) | 0.31 (1.08) | 2.01 × 10−5 | −0.35 (0.80) | 0.43 (1.00) | 0.0002 | −0.25 (0.82) | 0.21 (1.14) | 0.0187 | 0.0006 | 0.0192 |
| N-Acetylgalactosamine-1 N-Acetylmannosamine-1 N-Acetylglucosamine-1 |
0.29 (1.04) | −0.29 (0.87) | 2.46 × 10−5 | 0.18 (0.94) | −0.41 (0.77) | 0.0015 | 0.39 (1.12) | −0.19 (0.94) | 0.0040 | 0.0008 | 0.0226 |
Average values of the normalized data of each group are shown. Standard deviations are shown in parenthesis. Association was tested between cases and controls by Student's t-test. Meta-analysis of UIP and NSIP was performed. To correct for multiple testing; the false discovery rate (FDR) Q value was calculated. ILD, interstitial lung disease; CLD, chronic lung disease; RA, rheumatoid arthritis; UIP, usual interstitial pneumonia; NSIP, non-specific interstitial pneumonia; ILD(+)RA, RA patients with ILD; CLD(–)RA, RA patients without CLD; UIP(+)RA, RA patients with UIP; NSIP(+)RA, RA patients with NSIP; FDR, false discovery rate.